Noggin Combined With Human Dental Pulp Stem Cells to Promote Skeletal Muscle Regeneration

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Muscle Physiology

Background:

• Dental pulp stem cells (DPSCs) show promise for muscle injury repair due to their regenerative potential.
• Current limitations in myogenic induction efficiency of DPSCs hinder their clinical application in muscle regeneration.
• The precise mechanisms regulating DPSC myogenic differentiation remain largely unknown.

Purpose of the Study:

• To investigate the effect of Noggin, a bone morphogenetic protein (BMP) antagonist, on the myogenic differentiation of human DPSCs.
• To elucidate the role of BMP/Smad signaling in Noggin-mediated DPSC differentiation and satellite cell generation.
• To evaluate the therapeutic efficacy of Noggin-treated DPSCs in a mouse model of volumetric muscle loss (VML).

Main Methods:

• Human DPSCs were treated with Noggin to assess effects on myotube formation and myogenic marker expression.
• Skeletal myogenic differentiation (MyoD) and satellite cell (SC) marker expression (Pax7) were analyzed.
• BMP4 and Noggin effects on p-Smad1/5/9 signaling pathway were investigated.
• Noggin-pretreated DPSCs were implanted into VML mouse models to evaluate muscle regeneration and scar tissue reduction.

Main Results:

• Noggin treatment significantly promoted myotube formation and accelerated skeletal myogenic differentiation (MyoD) in DPSCs.
• Noggin enhanced the generation of Pax7-positive satellite-like cells and increased myogenic and SC marker expression.
• Noggin antagonized BMP4-induced p-Smad1/5/9 activation, suggesting a role in regulating BMP signaling.
• Implantation of Noggin-treated DPSCs in VML mice resulted in significant defect size reduction and decreased scar tissue formation.

Conclusions:

• Noggin effectively promotes myogenic differentiation and satellite-like cell production from DPSCs by modulating BMP/Smad signaling.
• Noggin-treated DPSCs enhance muscle regeneration and reduce scar tissue in a VML model.
• These findings highlight the potential of Noggin-modified DPSCs as a cell-based therapy for muscle injuries.